Hansoh Pharmaceutical Group Company Limited (HANSOH PHARMA) filed its Monthly Return for the period ended 31 July 2026, confirming stable share capital dynamics and ongoing convertible bond exposure.
Authorised and Issued Share Capital • Authorised share capital remained unchanged at 20.00 billion ordinary shares with a par value of HKD 0.00001, equivalent to HKD 0.20 million. • Issued share count held steady at 6.06 billion ordinary shares; no treasury shares were held or cancelled during the month.
Public Float Compliance • The company affirmed compliance with Hong Kong Main Board Rule 13.32, maintaining at least the initial prescribed public-float threshold of 16.21 % of issued shares.
Convertible Bonds Position • Zero-coupon convertible bonds due 2033, issued on 3 February 2026, remained outstanding at HKD 4.68 billion. • Conversion price: HKD 57.39 per share. • Full conversion would add up to 81.55 million new shares, but no conversions occurred in July.
Equity Incentives and Other Instruments • No share options, warrants, or other equity-settled instruments were issued, exercised, or lapsed during the month. • The company reported no other share movements, repurchases, or treasury share transfers.
Conclusion HANSOH PHARMA’s July filing signals capital stability, with the share base unchanged and adequate public float maintained. The outstanding HKD 4.68 billion zero-coupon convertible bond represents the primary potential source of future share dilution, equivalent to 1.35 % of current issued shares if fully converted.
Comments